

**OMNIPAQUE 300 (Iohexol)**

|                            |   |
|----------------------------|---|
| <b>Trade Name</b>          | Omnipaque   |
| <b>Class</b>               | Water-soluble, non-ionic contrast solution  |
| <b>Mechanism of Action</b> | Radio-opaque contrast medium  |
| <b>Indications</b>         | Identification of central venous catheter position  |
| <b>Contraindications</b>   | <p>Known hypersensitivity to Iodine</p> <p>Hyperthyroidism</p> <p>Use with caution in patients with diabetes or renal or hepatic impairment</p> <p>Asthmatics have increased risk of side effects of contrast medium</p>  |
| <b>Supplied As</b>         | 300mg bottle containing 647 mg of iohexol per mL which is equivalent to <b>300mg/mL</b> of iodine   |
| <b>Dilution</b>            | N/A   |
| <b>Dosage</b>              | <b>0.5mL</b> irrespective of the size of the catheter   |
| <b>Interval</b>            | Single bolus.   |
| <b>Administration</b>      | <p>Intravenous (within line lumen).<br/>Does not need to go through a filter.<br/>Inject through the smart site.</p> <p>Inject <b>0.5mL</b> of contrast and take the XRay a minute later ie: not at exactly the same time as the contrast is being given.<br/>After the XRay remove contrast medium from the line if able (by drawing back on the syringe until blood almost meets the connector) and discard.</p> <p>When the line position has been confirmed and no more contrast is needing to be injected then remove and replace the smart site as the contrast can block it causing high line pressures.</p> |
| <b>Compatible With</b>     | Do not mix with other medications or IV fluids  |
| <b>Incompatible With</b>   | Do not mix with other medications or IV fluids  |
| <b>Interactions</b>        | Iodinated contrast media can interfere with lab tests for bilirubin, protein, iron, copper, calcium and phosphate. If possible it is better to avoid performing contrast examinations on the same day that assays for these substances are requested.   |
| <b>Monitoring</b>          | Basic physiological variables: baby's colour and respirations (if not ventilated), pulse, saturations.  |

|                          |  |
|--------------------------|--|
| <b>Stability</b>         | Single use only –discard immediately after use   |
| <b>Storage</b>           | Store unopened vials at 2 – 30°C<br>Protect from light   |
| <b>Adverse Reactions</b> | Adverse reactions are rare but may include nausea, vomiting, diarrhoea, angioedema, anaphylaxis, peripheral vasodilatation, hypotension, cardiac arrhythmia, thrombophlebitis, renal impairment (usually transient), chills, sweating, agitation and seizures. |
| <b>Metabolism</b>        | Excreted un-metabolised in the urine   |
| <b>Comments</b>          | Injection technique should aim to minimise volume delivered to the baby's circulation. For sterile setup technique, see Neonatal Handbook.   |
| <b>References</b>        | <a href="http://www.medsafe.govt.nz">www.medsafe.govt.nz</a> – Omnipaque NZ Data Sheet   |
| <b>Updated By</b>        | A Lynn, B Robertshawe from Ultravist Protocol June 2011<br>A Lynn, B Robertshawe Dec 2012 (re-order profile)<br>A Lynn, R Sinclair Jan 2018 (change dose and timing of XRay) Dec 2018 – change smartsite after injection                                       |